wired In his compilation, Catalin Cariko also spoke, among other things, that the pace and effectiveness of development of Pfizer-Biontech’s RNA-based Covid vaccine has exceeded all scientific expectations. However, Catalin Cariko was not shocked by the huge success of the technology by the force of surprise. “We didn’t chew our nails excitedly, I knew what our vaccine might be capable of,” Biontech Vice President Katalin Carrico told the newspaper. Forbes As checked.
The Hungarian biochemist has been in development since 1989, his research laid the foundations for Biontech and Moderna’s current Covidvaccine project, and he was also the one who ran German Biontech scientists from his Philadelphia home during quarantine.
The British paper describes him as a “passionate and obsessive researcher” who always spices up what he says with scientific data, dates and experiments. He wrote that Kariko was impressed by the scale of production and the fact that 200 million people had already been vaccinated with their vaccine, but seemed impatient about how long it took mRNA technology to become acceptable. But he noted that science has long known it as a “magic potion.”
What they knew could work in theory, they encountered many obstacles in practice. It took many years before—from the 2000s, along with Drew Wiseman of the University of Pennsylvania—to create a synthetic mRNA molecule to which experimental mice respond well. It finally happened in 2004, but even then, it was a “painful process that killed many mice,” Wiseman said in a review of the Forbes article.
Hope is a missionary
Regardless, however, Carrico believes the method can provide an answer to treating a large number of ailments, and no matter how many professional conferences he has attended, RNA has been consistently mentioned as a potential solution. “I asked everyone what he was working on and what they said, I brought up mRNA for it to help. Even for baldness,” said the Hungarian scientist with a laugh. It was no coincidence that he felt in his surroundings that – quoting a colleague – Carlo “a missionary helped us think of all the possibilities.”
Influenza is targeted
According to Wired, the best chance is that it’s not another exotic infection, but rather a well-known flu that can be used against mRNA technology – it kills about 300,000 people a year worldwide. In addition to Kariko, another researcher of Hungarian origin, Norbert Bardi, is working on this latest research at the University of Pennsylvania, whose main project is to develop a truly effective influenza vaccine based on mRNA. “They want to produce a vaccine that affects many influenza viruses at once and it shouldn’t be given every year, because it would provide years of protection. Experiments in mice are really encouraging, ferret trials are coming soon, hopefully this year,” Bardi said.